Abstract
Measles, mumps, and rubella-specific IgG antibodies were evaluated in 134 healthy infants routinely immunized with trivalent live attenuated measles-mumps-rubella (MMR) vaccine at one year of age. Blood samples were collected just before, and at 1, 3, and 12 months after MMR. Specific IgG was measured by commercial enzyme immunoassays. Before vaccination, 98.5%, 99.2%, and 98.5% of the infants tested were seronegative for measles, mumps, and rubella, respectively. One year after MMR, 16.4% and 22.4% of vaccinees lacked demonstrable antibody to measles and mumps while none were found to be seronegative for rubella. Response profile analysis revealed primary failure rates of 12.1% (measles) and 8.6% (mumps) while 4% (measles) and 13.8% (mumps) of the infants responded initially but became seronegative within one year. These observations suggest that earlier administration (at age 18 months) of the second dose of MMR may be more desirable than revaccination at school entry.
Résumé
Les anticorps IgG spécifiques à la rougeole, les oreillons et la rubéole ont été évalués chez 134 enfants en bonne santé qui avaient été systématiquement immunisés avec un vaccin associé Rougeole-Oreillons-Rubéole (ROR), vivant et atténué, à l’âge d’un an. Des prélèvements sanguins ont été effectués juste avant l’administration du vaccin ROR, puis à des intervalles de 1, 3, et 12 mois par la suite. Le dosage immunoenzymatique de l’IgG spécifique a été effectué grâce à des préparations de commerce. Avant l’immunisation, les taux de séronégativité étaient de 98,5 %, 99,2 %, et 98,5 % pour la rougeole, les oreillons, et la rubéole respectivement. Un an après l’immunisation ROR, la présence d’anticorps contre la rougeole et les oreillons ne pouvait être demontrée chez 16,4 % et 22,4 % des enfants vaccinés, alors qu’aucun ne s’avérait séronégatif pour la rougeole. L’analyse des profils de réaction a révélé des taux d’échec primaire de 12,1 % pour la rougeole et 8,6 % pour les oreillons, alors que 4 % (rougeole) et 13,8 % (oreillons) des enfants sont devenus séronégatifs durant l’année après avoir manifesté une réaction initiale. Ces observations suggèrent que l’administration précoce (à 18 mois) de la seconde dose de vaccin ROR pourrait être préférable à la revaccination au moment de l’entrée à l’école.
References
- 1.Christenson B, Bottiger M. Changes of the immunological patterns against measles, mumps, and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule. Vaccine. 1991;9:326–29. doi: 10.1016/0264-410X(91)90058-E. [DOI] [PubMed] [Google Scholar]
- 2.Cutts FT, Markowitz LE. Success and failures in measles control. J Infect Dis. 1994;170(suppl1):S32–S41. doi: 10.1093/infdis/170.Supplement_1.S32. [DOI] [PubMed] [Google Scholar]
- 3.Matson DO, Bynington C, Canfield M, et al. Investigation of a measles outbreak in a fully vaccinated school population including serum studies before and after vaccination. Pediatr Infect Dis J. 1993;12:292–99. doi: 10.1097/00006454-199304000-00007. [DOI] [PubMed] [Google Scholar]
- 4.Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. New Engl J Med. 1994;331:1397–402. doi: 10.1056/NEJM199411243312101. [DOI] [PubMed] [Google Scholar]
- 5.Whittler R, Veit BC, McIntyre S, et al. Measles revaccination response in a school-age population. Pediatrics. 1991;88:1024–30. [PubMed] [Google Scholar]
- 6.National Advisory Committee on Immunization. Canadian Immunization Guide. 4th. Ottawa: Health Canada; 1993. pp. 70–77. [Google Scholar]
- 7.National Advisory Committee on Immunization. Supplementary statement on measles elimination in Canada. Can Commun Dis Rep. 1996;22:9–15. [PubMed] [Google Scholar]
- 8.Mitchell LA, Tingle AJ, Shukin R, et al. Chronic rubella vaccine-associated arthropathy. Arch Int Med. 1993;153:2268–74. doi: 10.1001/archinte.1993.00410190114013. [DOI] [PubMed] [Google Scholar]
- 9.Bakshi SS, Cooper LZ. Rubella and mumps vaccines. Pediatr Clin North Am. 1990;37:651–68. doi: 10.1016/S0031-3955(16)36909-7. [DOI] [PubMed] [Google Scholar]
- 10.Boulianne N, DeSerres G, Ratnam S, et al. Levels of measles, mumps, and rubella antibodies in children 5 to 6 years after immunization: Effect of vaccine type and age at vaccination. Vaccine. 1995;13:1611–16. doi: 10.1016/0264-410X(95)00098-L. [DOI] [PubMed] [Google Scholar]
- 11.Christenson B, Bottiger M. Measles antibody: Comparison of long-term vaccination titers, early vaccination titers and naturally acquired immunity to and booster effects on the measles virus. Vaccine. 1994;12:129–33. doi: 10.1016/0264-410X(94)90049-3. [DOI] [PubMed] [Google Scholar]
- 12.Miller E, Hill A, Morgan-Capner P, et al. Antibodies to measles, mumps, and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine. 1995;13:799–802. doi: 10.1016/0264-410X(94)00086-3. [DOI] [PubMed] [Google Scholar]
- 13.Ratnam S, West R, Gadag V, Burris J. Measles immunization strategy: Measles antibody response following MMRII vaccination of children at one year of age. Can J Public Health. 1996;87:97–100. [PubMed] [Google Scholar]
- 14.Davidkin I, Valle M, Julkunen I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination: A nine year follow-up. Vaccine. 1995;13:1617–22. doi: 10.1016/0264-410X(95)00064-8. [DOI] [PubMed] [Google Scholar]
- 15.Christenson B, Bottiger M. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults. Vaccine. 1994;12:41–45. doi: 10.1016/0264-410X(94)90009-4. [DOI] [PubMed] [Google Scholar]
- 16.Bishal DM, Bhatt S, Miller LT, Hayden GF. Vaccine storage practices in pediatric offices. Pediatrics. 1992;89:193–96. [PubMed] [Google Scholar]
- 17.DeSerres G, Boulianne N, Meyer F, Ward BJ. Measles vaccine efficacy during an outbreak in a highly vaccinated population: Incremental increase in protection with age at vaccination up to 18 months. Epidemiol Infect. 1995;115:315–23. doi: 10.1017/S0950268800058441. [DOI] [PMC free article] [PubMed] [Google Scholar]